Extracellular vesicles (EVs) in synovial fluid (SF) are gaining increased recognition as important factors in joint homeostasis, joint regeneration, and as biomarkers of joint disease. A limited number of studies have investigated EVs in SF samples of patients with joint disease, but knowledge on the role of EVs in healthy joints is lacking. In addition, no standardized protocol is available for isolation of EVs from SF. Based on the high viscosity of SF caused by high concentrations of hyaluronic acid (HA) Á a prominent extracellular matrix component Á it was hypothesized that EV recovery could be optimized by pretreatment with hyaluronidase (HYase). Therefore, the efficiency of EV isolation from healthy equine SF samples was tested by performing sequential ultracentrifugation steps (10,000g, 100,000g and 200,000g) in the presence or absence of HYase. Quantitative EV analysis using high-resolution flow cytometry showed an efficient recovery of EVs after 100,000g ultracentrifugation, with an increased yield of CD44' EVs when SF samples were pretreated with HYase. Morphological analysis of SF-derived EVs with cryo-transmission-electron microscopy did not indicate damage by high-speed ultracentrifugation and revealed that most EVs are spherical with a diameter of 20Á200 nm. Further protein characterization by Western blotting revealed that healthy SF-derived EVs contain CD9, Annexin-1, and CD90/Thy1.1. Taken together, these data suggest that EV isolation protocols for body fluids that contain relatively high amounts of HA, such as SF, could benefit from treatment of the fluid with HYase prior to ultracentrifugation. This method facilitates recovery and detection of CD44' EVs within the HA-rich extracellular matrix. Furthermore, based on the findings presented here, it is recommended to sediment SF-derived EVs with at least 100,000g for optimal EV recovery.
L ately there has been an increased recognition of the role of extracellular vesicles (EVs) in joint regeneration and joint disease, and suggestions have been made for EV-based clinical applications (1) . In this context, EVs derived from synovial fluid (SF) are currently being investigated to unravel their role in these processes and their biomarker potential for joint disease.
Several studies have examined EVs isolated from SF (2Á19). In most of these studies EVs have only been isolated from human SF obtained from inflamed joints. The fact that studies did not include samples from healthy controls is mainly because of ethical constraints concerning joint puncture in healthy subjects and the resulting low availability of healthy samples from the clinic.
However, in order to fully understand the role of EVdriven (patho)physiological processes in joints, knowledge about EVs in healthy joints is of utmost importance. Animal studies can ultimately give answers, but small animal models (rodents) do not provide sufficient volumes of SF for EV isolation, nor are their joints representative for the human situation in a biomechanical sense. The horse, on the contrary, is a well-suited species for obtaining large volumes of healthy SF. Furthermore, equine and human joints show great similarities (20) and the horse is an acknowledged animal model for human joint disease (21, 22) .
Since all body fluids have their own characteristic composition, EV isolation protocols need to be tailored for each specific fluid (23Á25). SF, especially if derived from healthy joints, is very viscous due to high concentrations of high-molecular-weight hyaluronic acid (HA), also known as hyaluronan (26, 27) . Although some previous studies included hyaluronidase (HYase) treatment of SF prior to EV isolation (10, 11) , the effect of HYase treatment on EV recovery has not been investigated in detail. In fact, an optimized protocol for EV recovery from SF is lacking and documented protocols for EV isolation and analysis differ widely and are often incomplete.
In the current study, the recovery of EV subsets from healthy equine joint-derived SF was analysed using different centrifugation protocols in the absence or presence of HYase. Quantitative and qualitative analysis of EV subsets was performed using single-EV-based high-resolution flow cytometric (FCM) analysis (28, 29) , cryo-transmissionelectron microscopy (cryo-TEM) (30) , and Western blotting. Based on the results, suggestions are made for an optimized protocol for EV isolation from SF.
Materials and methods
Experimental study design, ultracentrifugation steps, and density gradient composition The complete work flow for this study and the specific EV isolation protocol are depicted in Fig. 1 . The protocol was based on earlier protocols used for EV isolation from SF as summarized in Table I (2Á19) but was more comprehensive than most of these, as it was made to meet the recently defined minimal requirements for functional EV studies (31) . The technical specifications of ultracentrifugation steps (centrifugation speeds, rotor types, etc.) and density gradient floatation are indicated in the individual sections. For all ultracentrifugation steps, rotors with swing-out buckets were used. The compositions of the OptiPrep and sucrose density gradients are presented in Supplementary Fig. 1 .
Reagents and antibodies
HYase type II from sheep testes, PKH67 green fluorescent dye with diluent-C (MIDI-67-1KT kit), and OptiPrep TM density gradient medium (iodixanol 60% w/v) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Phosphate buffered saline (PBS) was purchased from Gibco (Thermo Scientific, Waltham, MA, USA). Protifar protein powder was purchased from Nutricia (Zoetermeer, the Netherlands). Sucrose was purchased from J.T. Baker (Avantor Performance Materials, Center Valley, PA, USA). The following primary antibodies were used for Western blotting and/or high-resolution FCM: anti-CD9 (clone HI9, Biolegend, San Diego, CA, USA), anti-CD44 (clone IM7, PE-conj., eBioscience, San Diego, CA, USA), isotype control for anti-CD44 (rat IgG2bk, 
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(page number not for citation purpose) EV-depleted RPMI/10% FBS, used to stop the PKH67 staining process, was prepared by making a stock solution of 30% (v/v) FBS (PAA Laboratories, GE Healthcare) in roswell park memorial institute medium (RPMI) (Gibco, Thermo Scientific), which was cleared of EVs by ultracentrifugation at 100,000g for 16 h at 48C (as described above), filtered through a 0.22-mm filter, stored in aliquots at (208C, and diluted 3 ) in RPMI prior to use.
This protocol for EV depletion of reagents is a standard procedure in our lab (29) and results in very few remaining EVs if the following precautions are taken: a) start with dilutions of BSA (max 5%) and FBS (max 30%) in the buffer/medium of choice; b) use a swing-out rotor; c) use a centrifugation time of at least 16 h; d) leave at least 5 ml of supernatant above the EV pellet.
Collection of equine SF SF samples were collected post-mortem with owner consent from adult warmblood horses that were euthanized for reasons other than joint disease at the Utrecht University Equine Hospital. Healthy SF (5Á10 ml) without blood contamination was collected by arthrocentesis from the carpal joints within 2 h after euthanasia and cleared from cells by centrifugation at 2,700g (4,000 rpm) 30 min at room temperature (RT) in a Hettich Universal 32 centrifuge (Hettich, Tuttlingen, Germany) with rotor 1619. Cell-free samples were aliquoted and stored at (808C.
EV isolation and labelling for high-resolution FCM and Western blotting (CD9 and CD44) The stored, healthy, cell-free SF of 2 donors (adult horses; 4 ml/donor) was thawed and for each donor divided into 2 aliquots of 2 ml. Aliquots were incubated either with 40 ml PBS or with 40 ml HYase solution (1,500 U/ml in H 2 O) for 15 min in a water bath at 378C while vortexing every 5 min. Protein aggregates were removed by centrifugation at 1,000g for 10 min at RT in an Eppendorf centrifuge (Hettich Mikro 200R with rotor 2424A). The supernatants were transferred into SW60 tubes (BeckmanCoulter) and gently mixed with 2 ml PBS. EVs were pelleted with 3 sequential ultracentrifugation steps of 10,000g (35 min, 9,900 rpm; RCF average 10,066g; RCF max 13,205g; k-factor 1667.7), 100,000g (65 min, 31,300 rpm; RCF average 100,618g; RCF max 132,000g; k-factor 166.8), and 200,000g (65 min, 44,000 rpm; RCF average 198,835g; RCF max 260,849g; k-factor 84.4) using an SW60-Ti rotor in a Beckman-Coulter Optima TM L-90K or Optima TM XPN-80 ultracentrifuge at 48C. EV pellets were suspended in a mixture of 20 ml EV-depleted PBS/ 0.1% BSA and 30 ml diluent-C. To each sample 4 ml anti-CD44-PE antibody (0.2 mg/ml) or 4 ml anti-IgG2bk-PE isotype control antibody (0.2 mg/ml) was added and incubated for 1 h at RT on a shaker. Prior to use the anti-CD44-PE and the IgG2bk-PE stock solutions were centrifuged in order to pellet aggregates (21,000g, 20 min, 48C; Hettich Mikro 200R with rotor 2424A). After CD44-PE or isotype labelling 50 ml diluent-C was added (to create a total volume of 100 ml) and this was mixed with PKH67 staining mix (1.5 ml PKH67 in 100 ml diluent-C). After 3 min incubation at RT, 50 ml of EVdepleted RPMI/10% FBS was added to stop the staining process. Labelled EVs (250 ml) were then mixed with 1.5 ml pure OptiPrep (iodixanol 60% w/v) and used for density gradient floatation. A dye background control sample (20 ml EV-depleted PBS/0.1% BSA'30 ml diluent-C, without EVs) was taken along during the entire procedure of PKH67 labelling, anti-CD44 labelling, and OptiPrep gradient floatation. High-resolution FCM of this control sample did not show significant background in gradient fractions of interest (data not shown).
EV isolation and labelling for cryo-TEM and
Western blotting (Annexin-1 and CD90/Thy1.1) The stored, healthy, cell-free SF of 2 donors (adult horses; 6 ml/donor) was thawed, pooled, and divided into 6 aliquots of 2 ml. Each aliquot was incubated with HYase and cleared from protein aggregates as described above. Supernatants were pooled, transferred into MLS50 tubes (Beckman-Coulter) (3 ml per tube) and gently mixed with 2 ml PBS. EVs were pelleted with 2 sequential ultracentrifugation steps of 10,000g (35 min, 10,000 rpm; RCF average 8,025g; RCF max 10,730g; k-factor 1,777) and 200,000g (120 min, 50,000 rpm; RCF average 200,620g; RCF max 268,240g; k-factor 71.7) using an MLS50 rotor in a Beckman-Coulter Optima TM MAX-E ultracentrifuge at 48C. Note that by omitting the 100,000g centrifugation step, all EVs that would have been recovered in a separate 100,000g step are now recovered in the 200,000g step (in this paper these vesicles will be referred to as ''100/200,000g EVs''). The EV pellets of each of 4 corresponding tubes were resuspended in PBS, pooled (final volume 250 ml EVs), and mixed with 1.25 ml 2 M sucrose solution (in PBS) and used for sucrose density gradient floatation.
Density gradient floatation of EVs
OptiPrep TM density gradient floatation Pelleted 10,000g, 100,000g, or 200,000g EVs, labelled with anti-CD44-PE (or isotype control) and PKH67, mixed with pure OptiPrep (iodixanol 60% w/v) (total volume01.75 ml) in SW40 tubes (Beckman-Coulter) were carefully overlaid with 15 volumes of 700-ml OptiPrep solutions with decreasing density (pure OptiPrep diluted in PBS) to create continuous gradients of951Á0% iodixanol ( Supplementary Fig. 1 ). Gradients were centrifuged at 200,000g for 16 h at 158C (Beckman-Coulter Optima TM L-90K or Optima TM XPN-80 centrifuge; SW40-Ti rotor; 39,000 rpm; RCF average 192,072g; RCF max 270,519g; k-factor 144.5). After centrifugation 12 fractions of 1 ml were carefully collected from top (fraction 1) to bottom (fraction 12) by using a P1000 pipette and OptiPrep densities were calculated by refractometry (32) .
Sucrose density gradient floatation Pelleted 10,000g or 100/200,000g EVs, mixed with 2 M sucrose solution (total volume 01.5 ml) in MLS50 tubes (Beckman-Coulter) were carefully overlaid with sucrose solutions of 1.4, 0.4, and 0 M (sucrose in PBS) to create 2 discontinuous sucrose gradients ( Supplementary Fig. 1 ). Gradients were centrifuged at 200,000g for 16 h at 48C (Beckman-Coulter Optima TM MAX-E centrifuge; MLS50 rotor; 50,000 rpm; RCF average 200,620g; RCF max 268,240g; k-factor 71.1). After centrifugation 5 fractions of 1 ml were collected from bottom (fraction 5) to top (fraction 1) by using a peristaltic pump connected to a capillary tube reaching to the bottom of the centrifuge tube. Fraction densities were calculated by refractometry.
Single-EV-based high-resolution FCM
OptiPrep gradient fractions 1Á9 (containing 10,000g, 100,000g, or 200,000g EVs from SF treated with or without HYase) were diluted 1:20 in PBS and single-EV-based high-resolution FCM was performed using an optimized jet-in-air-based BD Influx TM flow cytometer (Becton Dickinson, San Jose, CA, USA), as previously described in detail (28, 29, 33) . Briefly, detection of EVs by this system is based on threshold triggering by the fluorescence emitted after excitation of fluorescently labelled particles passing the first laser (FL1 signal). The threshold for triggering on FL1 was adjusted to allow an event rate of 510 events/s when clean PBS was analysed. The threshold level was kept identical for all measurements in this study. Forward scatter (FSC) of EVs was measured through an adapted small particle detector with a collection angle of 15Á258 (reduced wide-angle FSC), by using a high numerical aperture and long working distance lens and by installing a 5-mm obscuration bar in front of the FSC collection lens. These settings allow the best distinction of FSC and FL1 fluorescence for fluorescent 100 nm and 200 nm yellow-green (505/515) carboxylated polystyrene beads (FluoSpheres, Life Technologies, Thermo Scientific, Waltham, MA, USA) with which the flow cytometer was calibrated. For experiments a 140-mm nozzle was used. The sheath fluid pressure was kept between 4.98 and 5.02 psi and was monitored by an external pressure meter. The sample pressure was set to 4.29 psi. Data were acquired using BD FACS TM Software v1.0.1.654 (BD Biosciences, San Jose, CA, USA) and analysed with FlowJo v10.07 software (FlowJo, Ashland, OR, USA).
For time-based quantification of EVs per gradient fraction, the amount of PKH67 events (FL1 signal) per 30 s was measured and the percentage of CD44-PE positive events (FL3 signal) was assessed relative to the isotype control condition. Total EV concentrations per ml of SF were calculated based on the event rate measurement per 30 s and a volume measurement of 14.5 ml per 30 s. Volume measurement was performed by a 30Á60 min measurement of an H 2 O sample and calculating the weight difference of the tube over time.
Western blotting For OptiPrep gradients, 375 ml of fractions 2Á7 were pooled (i.e. fractions 2'3, 4'5, and 6'7) since these fractions contained the highest concentration of EVs according to high-resolution FCM. Pooled fractions (750 ml each) were diluted in SW28 tubes (Beckman-Coulter) by adding 37 ml PBS. EVs were pelleted at 100,000g for 60 min at 48C (Beckman-Coulter Optima TM L-90K or Optima TM XPN-80 centrifuge; SW28 rotor; 28,000 rpm; RCF average 103,745g; RCF max 141,371g; k-factor 245.5).
For sucrose gradients, fractions 2, 3, and 4 were pooled and 1 ml of pooled sample mixed with 11 ml PBS was centrifuged in SW40 tubes (Beckman-Coulter) to pellet EVs by using the identical protocol as for pelleting EVs for cryo-TEM.
Finally, EV pellets were suspended in 70 ml non-reducing SDS-PAGE sample buffer [50 mM TRIS (pH 6.8), 2% SDS, 10% glycerol, 0.02% bromophenol blue], heated at 1008C, run on 4Á20% Criterion TGX gels (Bio-Rad, Hercules, CA, USA), and transferred onto 0.2 mm polyvinylidene difluoride (PVDF) membranes. After blocking (1 h, 5% Protifar in PBS 0.1% Tween-20) proteins were labelled with primary antibodies against CD9 (dilution 1:1,000), CD44 (dilution 1:400), Annexin-1 (dilution 1:400), and CD90/Thy1.1 (dilution 1:400) and a HRP-labelled secondary antibody (dilution 1:5,000) was used for detection by chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate, Thermo Scientific). Chemiluminescence was visualized using a ChemiDoc TM MP Imaging System (Bio-Rad, Hercules, CA, USA) and analysed with Bio-Rad Image Lab V5.1 software (Bio-Rad).
Cryo-TEM For cryo-TEM, sucrose gradient fractions 2, 3, and 4 (containing 10,000g or 100/200,000g EV) were pooled per gradient and diluted by adding 9 ml PBS to SW40 tubes (Beckman-Coulter). EVs were pelleted at 200,000g for 60 min at 48C (Beckman-Coulter Optima TM L-90K or Optima TM XPN-80 centrifuge; SW40-Ti rotor; 39,000 rpm; RCF average 192,072g; RCF max 270,519g; k-factor 144.5). EV pellets were carefully suspended in 20 ml PBS and stored on ice for 1Á2 h until vitrification using a Vitrobot TM Mark IV system (FEI, Eindhoven, Netherlands). Three microlitres of EV sample was directly placed onto a glow-discharged 2/2 copper grid (Quantifoil, Jena, Germany). Excess sample was removed with 595 filter paper (Schleicher & Schuell, Whatman Plc., Kent, UK) in the Vitrobot chamber for 1 s at 100% relative humidity, with subsequent plunging into liquid ethane (3.5 purity). Residual ethane was removed with filter paper and grids were stored in cryo-boxes under liquid N 2 for later imaging. For cryo-TEM, grids were transferred to a Gatan 626 cryo-holder (Gatan Inc., Pleasanton, CA, USA), which was inserted into a Tecnai TM 20 transmission electron microscopy (FEI) with LaB 6 filament operated at 200 kV. Images were acquired with a 4,000)4,000 Eagle charge coupled device (CCD) camera (FEI) at a 19,000) magnification, 5Á10 mm under focus.
For morphology of EVs, individual EVs were categorized as ''single EVs'' (1 EV with a single membrane), ''multi-membrane EVs'' (2 EVs merged together, or 1 EV with double membrane), ''collections of EVs'' (more than 2 EVs merged into 1 entity), or ''other small particles'' (very small vesicle-like particles without clear membrane). Single EVs were further subcategorized into ''spherical EVs'' (diameter ratio ]0.7) or ''tubular EVs'' (diameter ratio B0.7). Multi-membrane EVs and collections of EVs were counted as 1 entity. For size distribution of spherical EVs, the smallest and largest diameter of each individual EV was measured with the ''measure tool'' in ImageJ (1.48v) and the ''diameter ratio'' (smallest diameter/ largest diameter) was determined. The average diameter for each EV [(smallest'largest diameter)/2] was used for the size distribution graphs.
Statistical analysis
All data in bar graphs are plotted as means of individual measurements of 2 donors. Error bars in all graphs represent the range, indicating the highest and lowest observed values (n02). Statistical analysis for Figs. 6 and 7 was performed on data from 2 donors by using the total EV counts or the relative amount of CD44' EVs present in the 9 fractions of each gradient as data points. Logtransformation was carried out on total EV counts to gain normal distribution among the 9 fractions. Overall significant differences in all gradient fractions between 'HYase and (HYase were calculated in SPSS 22.0 software (IBM, Chicago, USA), using a linear mixed model, with ''donor'' as a subject and ''gradient fraction'' (0F1 to F9), ''centrifugation step'' (010,000g or 100,000g or 200,000g), and ''HYase treatment'' (0 'HYase or (HYase) as (repeated) fixed factors. Differences with p-values B0.05 were considered significant based on 95% confidence intervals.
Results
Quantification of EVs from SF with or without HYase treatment and detection of EV markers To characterize and quantify EVs from healthy SF and to investigate the effect of HYase treatment, EVs from equine SF were isolated based on differential centrifugation followed by density gradient floatation. Equine SF was harvested from healthy joints of 2 donors and the samples were processed as summarized in Fig. 1 and Supplementary Fig. 1 . Previously we analysed whether dilution of fresh SF (1:2 in EV-depleted PBS/0.1% BSA) prior to storage at (808C would benefit EV isolation and analysis. Since pre-dilution of SF resulted in inconsistent data and loss of EVs (data not shown), in the current protocol, fresh samples were not diluted prior to HYase treatment. After HYase treatment, a 1:1 dilution of the sample was performed.
PKH67-labelled EVs in OptiPrep gradient fractions were measured as single-vesicle events by high-resolution FCM (Fig. 2) . EVs were detected throughout fractions F2ÁF7 with densities between 1.02 and 1.16 g/ml. Highest concentration of EVs were found in gradient fractions F3ÁF5 (density 1.05Á1.10 g/ml). The majority of all EVs were recovered in the 100,000g centrifugation step, regardless of HYase treatment (Fig. 2a) . Total EV recovery (sum of 10,000g EVs'100,000g EVs'200,000g EVs in gradient fractions F2ÁF7) was not significantly affected by pretreatment with HYase. By using the event rate and the sample volume measurement during highresolution FCM analysis, the biological concentrations of EVs in healthy equine SF (calculated from the HYasetreated samples after OptiPrep density gradient) could be estimated at 7)10 8 EVs/ml. HYase treatment, however, substantially increased the number of EVs pelleting at 10,000g, whereas in the nontreated samples a higher number of EV tended to pellet at 200,000g (Fig. 2a) . In addition, differences in light scattering properties of EVs were observed between the HYase-treated and non-treated samples (most clear in arbitrary regions II and III in the 10,000g and 100,000g centrifugation steps and in regions III and IV in the 200,000g centrifugation step). Because light scattering of EVs is dependent on a range of factors, such as size, cargo, and membrane composition, these findings could be indicative for recovery of different EV subsets in II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV  II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV  II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV   II  I  III IV   II  I  III HYase-treated and non-treated samples after similar centrifugation conditions (Fig. 2b) .
The quantitative results obtained with single-EV-based high-resolution FCM (Fig. 2a) corroborate with the CD9 Western blot results of EVs in pools of the same gradient fractions ( Fig. 3; Supplementary Fig. 2a) . Similar to the recovery of PKH67-labelled EVs, HYase treatment resulted in a more efficient recovery of CD9' EVs after 10,000g pelleting, whereas the additional 200,000g step improved the recovery of CD9' EVs from the non-treated samples. When total CD9 signal (sum) of all gradient fractions was compared, HYase treatment resulted in approximately 10% more CD9' EVs.
In addition to CD9, selected as general EV marker (31), Annexin-1 and CD90/Thy1.1 were analysed on SF-derived EVs because of their relevance in the joint. Annexin-1 was previously found on neutrophil-derived EVs during inflammatory arthritis (11) , and CD90/Thy1.1 is a cell surface marker of fibroblasts in the synovial lining (34) . The latter was verified on primary equine fibroblastlike synoviocytes ( Supplementary Fig. 3 ). Indeed, both Annexin-1 and CD90/Thy1.1 could be detected on 10,000g and 100/200,000g EVs from healthy SF (Supplementary Fig. 2b ).
Cryo-TEM of EVs from healthy SF
Cryo-TEM investigation was performed in order to confirm intact EVs in our preparations and to determine size and shape of 10,000g versus 100/200,000g EVs from healthy SF (Fig. 4) . A typical distribution on the grids showed single intact vesicles (Fig. 4a) . In both the 10,000g and the 100/200,000g samples, only occasional clusters of EVs were seen (Fig. 4b) . Further, both the 10,000g and the 100/200,000g ultracentrifugation resulted in a large diversity of EV shapes and sizes, for which the spherical shape was most abundant, comprising about 65% of all EVs (Fig. 4c) . Of note, about 3Á8% of analysed particles were defined as ''other small particles'' (B20 nm and lacking a clear vesicle membrane) (Fig. 4f) . When evaluating the size distribution of spherical EVs (Fig. 4d) , 92Á98% of all EVs had diameters between 20 and 200 nm in both centrifugation conditions. The highest frequencies of EVs B100 nm, however, were found in the 100/200,000g centrifugation step (69% vs. 57% in the 10,000g step). The average diameter was 109 nm for 10,000g EVs (n088) and 90 nm for 100/200,000g EVs (n0105). Occasionally EVs were found with high electron-dense granules in their lumen (not quantified) (Fig. 4e) Quantification of CD44' EVs from healthy SF and the impact of HYase treatment Next, the impact of HYase treatment on the identification of specific EV subsets from SF was studied by exploring the detection of CD44' EVs. CD44 is expressed by various cell types (35) , including primary fibroblast-like synoviocytes in the synovial membrane ( Supplementary  Fig. 3 ). In healthy joints these fibroblasts are the candidate cell type for the production and release of EVs into the SF. Furthermore, CD44 is the HA receptor and Á if present on EVs in SF Á could be involved in binding to full-length HA in the extracellular matrix. Therefore, degradation of the extracellular matrix by HYase might be beneficial for the recovery of CD44' EVs. Indeed, CD44 was detected by Western blotting on 10,000g and 100,000g EVs from the HYase-treated samples, whereas for the non-treated samples CD44' EVs were only present in the 100,000g samples ( Supplementary Fig. 2c ).
Since Western blotting does not allow single EV analysis, individual CD44' EVs were quantified by single-EVbased high-resolution FCM (Figs. 5 and 6). CD44' EVs were detected in all centrifugation steps, with an increased yield for the HYase-treated samples when centrifuged at 10,000g (pB0.05) and 100,000g (pB0.01) (Figs. 5 and 6b ).
To get more insight into the distribution of the CD44' EVs throughout the density gradients, the CD44' population of EVs was compared to the total population of EVs (PKH67') ( Fig. 6) . Remarkably, the distribution of CD44' EVs in the density gradient fractions did not fully correlate with the distribution of the total EV population; CD44' EVs tend to float at a higher density than the bulk of EVs in the gradient (Fig. 6 ). In general, centrifugation at 100,000g contributes mostly to the recovery of CD44' EVs. Finally, the cumulative counts of CD44' EVs in all centrifugation steps (sum of event rates for 10,000g EVs'100,000g EVs'200,000g EVs present in gradient fractions F2ÁF7) clearly demonstrates a significantly less efficient recovery of these EVs in the 10,000g and 100,000g centrifugation steps (p B0.01) in the absence of HYase treatment (Fig. 7) .
Discussion
For developing a tailor-made protocol for EV isolation from SF, previously published reports were first evaluated to determine which protocols to date have been used for EV isolation from SF and to survey which important technical steps should be considered for a standardized protocol. Of 18 articles published between 1995 and 2016 reporting EV isolation from SF (Table I ) (2Á19), 17 involved samples from human patients with joint disease. Only one study investigated healthy SF (of rat, canine, and equine origin) (14) . In 6 publications, samples were pretreated with anticoagulant and in 2 publications enzyme treatment with HYase prior to ultracentrifugation was reported. In most cases, EVs were pelleted with maximally 20,500g. In only 4 publications were EVs pelleted at ]100,000g. Strikingly, there was only a single publication in which EVs were purified by floating in density gradients. In all other studies, fresh SF or the total ultracentrifugation pellets Á both cleared from large particles, but contaminated with other non-vesicular macromolecular structures in addition to EVs Á were used for analysis of SF-derived EVs.
Our protocol considered the earlier published work, but was more comprehensive and included density gradient floatation, as it was designed to meet the recently published minimal requirements for functional EV studies (31) . Importantly, apart from the 10,000g and 100,000g pelleting steps, which are centrifugation forces most often used in the field to isolate EVs from body fluids, an additional 200,000g pelleting step was included to isolate EVs from SF, as this is a very viscous body fluid. Because the SF samples for this study were taken from healthy joints without blood contamination, anticoagulant treatment was not included. In contrast, HYase treatment appeared to be an important step in our protocol, due to the high concentration of high-molecular-weight HA in SF (26, 27) . HA is a non-sulphated glycosaminoglycan and the most prominent component of the extracellular matrix of SF (27) . Because CD44 is an HA receptor and present on synovial fibroblasts, considered to be important EV producers in SF, we evaluated the recovery of CD44' EVs in the absence or presence of HYase treatment.
We here showed that enzymatic digestion of the large HA chains with HYase is beneficial for the isolation of CD44 (HA receptor) positive EVs from SF. Only after HYase treatment could the CD44' EVs be efficiently isolated, mainly after 100,000g ultracentrifugation. Although the recovery of total EVs (PKH67') was not significantly affected when omitting HYase treatment, significantly less CD44' EVs were recovered. Very recently the presence of HA-coated EVs was detected in SF (19) . One possible explanation for the lower detection of CD44' EVs in the absence of HYase treatment in our study could be masking of antibody detection due to HA binding. However, because the epitope of the anti-CD44 antibody (IM7 clone) used for CD44' EV detection is located outside the HA binding domain of CD44 (36), antibody shielding or steric hindrance of antibody binding is less likely the cause of lack of detection. We therefore conclude that the lower yield of CD44' EVs from non-HYase-treated samples is most likely due to the formation of complexes of these EVs with the large chains of non-degraded HA in SF and that HYase degrades HA and liberates EVs that are bound via CD44, resulting in increased EV yields. Nevertheless, if steric hindrance of antibody binding by HA did take place on EVs, it could also hamper other antibody-based detection assays, making HYase treatment indispensable. Based on our data, we propose HYase incubation of SF preceding EV isolation for efficient recovery of CD44' EVs. However, it should be noted that possible effects of HYase treatment should be evaluated on further downstream processing and analysis steps, for example, (micro)RNA analysis. For protein and lipid analysis, problems due to HYase are not expected, since general biomarker analysis of fresh SF is routinely preceded by HYase treatment.
The fact that most EVs were intact and no debris of damaged EVs was observed by cryo-TEM indicates that these EVs can withstand the high centrifugation forces used in our protocol (!100,000g). Nevertheless, the possibility of (functional) loss due to centrifugation and floatation procedures cannot be ruled out, which is important for future research aiming at functional testing of these EVs. Cryo-TEM analysis of EVs from healthy SF, isolated with 10,000g or 100/200,000g, followed by a sucrose density gradient, revealed a heterogeneous pool of particles with shapes comparable to findings in other body fluids (24, 30, 37, 38) . For SF, differential centrifugation steps did not separate EVs based on morphology, nor on size, although size distribution of spherical EVs did show a tendency for EVs !100 nm to be recovered at 10,000g (compared to 100/200,000g). The finding that 92Á98% of EVs in our study had diameters between 20 and 200 nm is considerably different from the larger particles (up to 400 nm) detected in SF from patients with inflammatory joint disease (6, 9, 10, 19) . These differences could be caused by differences in the methodology used to isolate EVs, for example, centrifugation protocols and density gradients. Alternatively, it might indicate that during disease different EV populations are present in the joint.
Recent data indicate that particular EV types (e.g. platelet-derived EVs present in blood plasma) have the tendency to aggregate due to ultracentrifugation, which can lead to false interpretation of particle size and marker analysis (39, 40 F4 F5 F6 F7  F9  F2  F1  F3  F8  F4 F5 F6 F7  F9  F2  F1  F3  F8   F4 F5 F6 F7  F9  F2  F1  F3  F8  F4 F5 F6 F7  F9  F2  F1  F3  F8   20 rarely observed by cryo-TEM analysis, indicating that even 200,000g pelleting did not induce major aggregation artefacts. In addition to very small EVs (20Á40 nm), other small particles (typically 520 nm) were observed. These structures differed from EVs by not having a clear membrane and usually having a darker and more homogenous core compared to the slightly larger EVs. Possibly, these very small particles could be lipoproteins, resembling cryo-EM preparations of very low density lipoprotein (VLDL) particles from blood (38, 41) or ice-crystal artefacts, as has been observed in ejaculates (37) . EVs isolated from healthy equine SF were positive for CD9, Annexin-1, CD90/Thy1.1, and CD44. Whereas CD9 is a common marker for EVs, Annexin-1 has so far Á in relation to the joint Á been known only as a proresolving anti-inflammatory marker on EVs in the inflammatory joints of patients with joint disease (11) . The current data show that Annexin-1 is also present on EVs in healthy SF, although at relatively low abundance. These Annexin-1' EVs may be derived from the few circulating immune cells present in healthy SF. For the bulk of SFderived EVs, however, a synoviocytic origin is more likely, because markers found on these EVs, for example, CD90/ Thy1.1 and CD44, are also highly expressed on primary fibroblast-like synoviocytes.
The interaction between HA and CD44' EVs in SF might be of functional interest during joint disease. Because the concentration and chain length of HA is dependent on the disease state of the joint (27), the interaction (or the lack thereof) between CD44' EVs and HA in the extracellular matrix might be altered when joint homeostasis is disturbed. This could have its functional effect by changing the freedom of movement of CD44' EVs in the joint space and thus changing the efficiency of interaction with target cells in the synovial membrane or the cartilage. CD44' EVs could also, by binding free HA chains, serve as transport vehicles for HA between cells and might facilitate its efficient delivery to target cells. In vitro studies have shown that when HA is delivered to CD44-expressing cells, the HAÁCD44 interaction on these cells results in an anabolic (and anti-inflammatory) cascade by inhibiting TNF-a-or IL-1b-induced matrix metalloproteinase (MMP) production and aggrecanase expression in chondrocytes and synovial cells, explaining the mechanism of action during HA therapy in arthritis (42) . Furthermore, triggering of fibroblast-like synoviocytes with HA evokes the production of more HA, dependent on the type of HA used (26, 43) . Finally, cell types with active HA synthesis (for the joint these are fibroblast-like synoviocytes and chondrocytes) contain an ''HA coat'' on protrusions of their plasma membrane (44) . CD44' EVs could use these high-affinity HA-coated areas to anchor to cells for further EV uptake or interaction.
While the importance of CD44-dependent EV interaction with HA has already been established in HA-related pathologies, such as cancer progression (45) , clarifying the role of EV-associated CD44 in healthy and diseased joints needs to be further substantiated since CD44 is not only a HA receptor, but also an important signalling molecule in various cell types (35) . With respect to the CD44ÁHA interaction on EVs, it is important to note that only specific forms of HA actively bind to CD44 (27) . The exact interaction and timing of this event during joint homeostasis, or the disturbance thereof, should be further investigated. Insight into this interaction could also be of importance for potential clinical applications, such as the incorporation of CD44' EVs or liposomes (loaded with pharmaceuticals) into HA-rich scaffolds for local controlled release of treatment during joint regeneration (1) .
Ultimately, the CD44' EV population in SF is likely an important functional EV subset, which might have distinct functions in healthy and diseased joints. Although infiltration of interstitial fluids into the SF during inflammation results in lower viscosity of the fluid, the HYase step needs to be taken into consideration for inflammatory SF as well, because increased production of low-molecular-weight HA during inflammation might provoke even more trapping of CD44' EVs into the extracellular matrix (27) . In addition, for other HAcontaining body fluids, such as pleural fluid, peritoneal fluid, and blood (46, 47) , sedimentation of EVs could be hampered by omitting the HYase step in the EV isolation protocol. This is an important consideration, since systemic accumulation of HA is often a poor prognostic factor in diseases like rheumatoid arthritis (48) , osteoarthritis (49) , liver disease (50) , and many epithelial cancers (51) . Hence to unveil the role of EVs in (patho)physiologic processes and to search for diseasespecific EV-based biomarkers, the addition of HYase during EV isolation from body fluids might be indispensable to avoid the loss of a potentially important CD44' EV subset.
Conclusion
To the best of our knowledge, this is the first detailed investigation in which EVs were isolated and analysed from healthy SF samples. In contrast to reports that claim that high-speed centrifugation of body fluids leads to formation of EV aggregates, EV isolation from SF can be performed with high-speed centrifugation up to 200,000g without substantial aggregate formation or damage to EVs. The majority of EVs from SF can be recovered at 100,000g. However, in the absence of HYase treatment a substantial amount of EVs is only recovered after 200,000g, while the CD44' EV subset is isolated inefficiently. The beneficial effect of HYase treatment on CD44' EV recovery from SF stresses the importance of tailor-made protocols for EV isolation from different body fluids. For the case of SF, in most EV isolation protocols up to now, neither HYase treatment nor a 200,000g centrifugation step was applied and often only centrifugation forces of maximally 20,500g were used. Based on our findings, this implies that in these studies EVs are possibly recovered suboptimally and specific subsets, such as the CD44' EVs, might therefore remain unnoticed. The design of a golden standard protocol for isolation of EVs from SF, however, remains difficult due to differences in SF composition between healthy and diseased joints, within different joint diseases, at different disease stages, and possibly between species. Taking into account that not only EV characteristics, but also the matrix composition wherein these EVs are present, determine the g-forces and time necessary for sedimentation, HYase treatment is an attractive option to at least eliminate HA-dependent matrix variations between SF samples and efficiently recover the biologically relevant CD44' EVs.
